肉毒杆菌毒素与良性前列腺增生
Botulinum toxin and benign prostatic hyperplasia.
作者信息
Ng Lay Guat
机构信息
Department of Urology, Singapore General Hospital, Singapore.
出版信息
Asian J Urol. 2018 Jan;5(1):33-36. doi: 10.1016/j.ajur.2017.11.003. Epub 2017 Nov 22.
Abstract
Benign prostatic hyperplasia (BPH) is a clinical condition where lower urinary tract symptoms are caused by both a physically obstructing prostate as well as tight smooth muscles around the bladder outlet. Treatment of this condition with botulinum toxin has been used since 2003, but this interest has somewhat died down after two large randomized controlled trials (RCTs) showing equivalence of results between their treatment and placebo arms. However, with review of animal studies and unexplained exaggerated effect of the placebo arms of the two RCTs, together with recent data of sustained benefits after 18 months of treatment, the place of botulinum toxin in the BPH field is probably still present.
摘要
良性前列腺增生（BPH）是一种临床病症，下尿路症状由物理性阻塞前列腺以及膀胱出口周围紧绷的平滑肌共同引起。自2003年以来，肉毒杆菌毒素一直被用于治疗这种病症，但在两项大型随机对照试验（RCT）表明其治疗组与安慰剂组结果相当之后，这种兴趣有所减弱。然而，通过回顾动物研究以及两项RCT中安慰剂组无法解释的夸大效果，再加上近期治疗18个月后持续获益的数据，肉毒杆菌毒素在BPH领域可能仍有一席之地。
相似文献
1
Botulinum toxin and benign prostatic hyperplasia.
Asian J Urol. 2018 Jan;5(1):33-36. doi: 10.1016/j.ajur.2017.11.003. Epub 2017 Nov 22.
2
Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia.
Urology. 2012 Oct;80(4):889-93. doi: 10.1016/j.urology.2012.06.004. Epub 2012 Jul 31.
3
Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia-A Spotlight in Reality.
Toxins (Basel). 2016 Apr 26;8(5):126. doi: 10.3390/toxins8050126.
4
Intraprostatic botulinum toxin type "A" injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double-blind, controlled trial using urodynamic evaluation.
Neurourol Urodyn. 2018 Mar;37(3):1031-1038. doi: 10.1002/nau.23390. Epub 2017 Aug 25.
5
Prostate botulinum A toxin injection--an alternative treatment for benign prostatic obstruction in poor surgical candidates.
Urology. 2005 Apr;65(4):670-4. doi: 10.1016/j.urology.2004.10.077.
6
Combination of intravesical prostatic protrusion and resistive index is useful to predict bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Int J Urol. 2016 Nov;23(11):929-933. doi: 10.1111/iju.13188. Epub 2016 Aug 21.
7
Botulinum toxin A injection to the bladder neck and urethra for medically refractory lower urinary tract symptoms in men without prostatic obstruction.
J Formos Med Assoc. 2009 Dec;108(12):950-6. doi: 10.1016/S0929-6646(10)60008-3.
8
Effect of terazosin on clinical benign prostatic hyperplasia in older adults.
J Am Geriatr Soc. 2003 Mar;51(3):424-6. doi: 10.1046/j.1532-5415.2003.51120.x.
9
10
[Preliminary results of botulinum toxin in the treatment of benign prostatic hyperplasia].
Prog Urol. 2007 Jun;17(4):796-800. doi: 10.1016/s1166-7087(07)92295-2.
引用本文的文献
1
Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade After Approval: General Versus Local Anesthesia for BotulinumtoxinA Detrusor Injection.
Toxins (Basel). 2024 Oct 28;16(11):462. doi: 10.3390/toxins16110462.
2
An Update on Minimally Invasive Surgery for Benign Prostatic Hyperplasia: Techniques, Risks, and Efficacy.
World J Mens Health. 2020 Oct;38(4):402-411. doi: 10.5534/wjmh.190076. Epub 2019 Aug 20.
3
Current consensus and controversies on male LUTS/BPH (part two).
Asian J Urol. 2018 Jan;5(1):8-9. doi: 10.1016/j.ajur.2017.11.007. Epub 2017 Dec 6.
本文引用的文献
1
Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia-A Spotlight in Reality.
Toxins (Basel). 2016 Apr 26;8(5):126. doi: 10.3390/toxins8050126.
2
Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis.
Int Urol Nephrol. 2016 Jan;48(1):19-30. doi: 10.1007/s11255-015-1153-3. Epub 2015 Nov 11.
3
A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia.
J Urol. 2014 Jul;192(1):150-6. doi: 10.1016/j.juro.2014.02.004. Epub 2014 Feb 7.
4
A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.
Eur Urol. 2013 Mar;63(3):496-503. doi: 10.1016/j.eururo.2012.10.005. Epub 2012 Oct 12.
5
Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
BJU Int. 2012 Dec;110(11 Pt C):E837-44. doi: 10.1111/j.1464-410X.2012.11288.x. Epub 2012 Jun 19.
6
Botulinum toxin injection for lower urinary tract dysfunction.
Int J Urol. 2013 Jan;20(1):40-55. doi: 10.1111/j.1442-2042.2012.03035.x. Epub 2012 May 9.
7
Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results.
Urology. 2009 Jan;73(1):90-4. doi: 10.1016/j.urology.2008.08.475. Epub 2008 Nov 8.
8
Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption.
Eur Urol. 2008 Jan;53(1):153-9. doi: 10.1016/j.eururo.2007.08.050. Epub 2007 Sep 4.
9
Effects of botulinum toxin A on the contractile function of dog prostate.
Eur Urol. 2007 Aug;52(2):582-9. doi: 10.1016/j.eururo.2007.03.002. Epub 2007 Mar 12.
10
Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia.
BJU Int. 2006 Nov;98(5):1033-7; discussion 1337. doi: 10.1111/j.1464-410X.2006.06479.x. Epub 2006 Sep 6.
Zotero 插件